Trial Profile
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets (100 mg, 200 mg and 300 mg Three Times Every Two Hours on One Day and q.d. for Another 2 to 3 Days) in Healthy Male and Female Volunteers, a Randomised, Doubleblind, Placebo-controlled Within Dose Groups Phase I Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 44370 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Aug 2014 New trial record